Amarantus BioScience President and CEO Publishes New Blog Entitled “LymPro Heading into 2014: Shifting the Diagnostic Paradigm in Alzheimer’s”


Amarantus BioScience, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's President and CEO, Gerald E. Commissiong. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus President and CEO, Gerald E. Commissiong, reflects on the changing landscape of US healthcare as the Affordable Care Act is implemented. He writes about the potential impact the "addition of new rules encouraging preventative measures" could have on the commercialization of LymPro. Read his full blog post on (

About Amarantus BioScience, Inc.

AmarantusBioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information, please visit

About is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.

View Comments (0)